Bioequivalence
Conditions
Brief summary
The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 9.5 mg/24 h transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch application. Each of both treatments will last for 11 days with a washout period of 14 days between the treatments.
Interventions
DRUGRID-TDS 9.5 mg/24 h
3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Sponsors
SocraMetrics GmbH
SocraTec R&D GmbH
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. sex: male 2. age: 18-55 years, inclusive 3. body-mass index2 (BMI): ≥18.5 kg/m² and ≤ 30.0 kg/m² 4. good state of health as determined by no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including vital sign) and/or ECG, as determined by the investigator 5. non-smoker or ex-smoker for at least 1 month 6. written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial
Exclusion criteria
1. existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient (especially sick sinus syndrome or conduction defects such as sino-atrial block, atrio-ventricular block) 2. existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient (especially predisposition to urinary obstruction and seizures) 3. existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient (especially active gastric or duodenal ulcers or predisposition to these conditions) 4. history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders 5. Subjects with chronic obstructive or other pulmonary diseases or bronchial asthma 6. known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations or previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch 7. subjects with severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator 8. systolic blood pressure \< 90 or \>139 mmHg 9. diastolic blood pressure \< 60 or \>89 mmHg 10. heart rate \< 50 bpm or \> 90 bpm 11. body weight below 50 kg 12. QTc interval \> 450 ms 13. laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator 14. ASAT \> 20% ULN, ALAT \> 10% ULN, bilirubin \> 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine \> 0.1 mg/dL ULN (limit of \> 0.1 mg/dL correspondents to of \> 9 μmol/l ULN). 15. positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test or anti-HCV-test 16. Presence or history of acute or chronic diseases especially of the skin, which could affect dermal absorption or metabolism, which may interfere with the bioavailability and /or the pharmacokinetics of the IMP based on assessment of the investigator 17. Skin abnormality (e.g. tattoo or scar) at the application site 18. acute or chronic diseases which may interfere with the pharmacokinetics of the IMP 19. history of or current drug or alcohol dependence 20. positive alcohol or drug test at screening examination 21. regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol per day 22. subjects who are on a diet which could affect the pharmacokinetics of the active ingredient 23. regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day 24. blood donation or other blood loss of more than 400 ml within the last 2 months prior to individual enrolment of the subject 25. administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the subject 26. regular treatment with any systemically available medication 27. subjects practising top-performance sports (more than 4 x 2 h per week) 28. subjects suspected or known not to follow instructions 29. subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC96-264 | from 96 to 264 hours after the first patch application | partial area under the plasma concentration vs. time profile for the time interval 96-264 hours |
| Cmax,96-264 | from 96 to 264 hours after the first patch application | maximum concentration in plasma during the nominal time interval 96-264 hours |
| Cmin,96-264 | from 96 to 264 hours after the first patch application | absolute minimum concentration within the nominal time interval 96-264 hours |
| Patch adhesion properties | at 96, 168 and 264 hours after the first Test patch application | lower one-sided 90% confidence limit for the mean of Test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | approximately 7 to 12 weeks, through study completion in case of follow-up | descriptive evaluation of frequency and intensity, relationship to the IMP, action taken, outcome, seriousness, period and treatment |
| inhibition of plasma butyrylcholinesterase (BuChE) | from first patch application until 24 hours after the last patch removal | % inhibition of BuChE activity in plasma in comparison to baseline |
| Skin irritation | from first patch removal until last patch removal (approx. 9 to 13 days) | frequency of scores for quantification of skin irritation per treatment and time point |
Countries
Germany
Outcome results
None listed